Grants for Small Businesses

This grant provides financial support to individuals, businesses, and organizations in Denver to create projects that promote active living, such as improving walkability and bikeability in their neighborhoods.

PLEASE NOTE: Addendum #3, dated 4/9/2024, has just been added to the opportunity. This Addendum extends the RFA application due date to 5/2/2024 at 4pm ET.PLEASE NOTE: Addendum #2, dated 3/26/2024, has just been added to the opportunity. Please click on View Grant Opportunity to view this material. PLEASE NOTE: Addendum #1, dated 3/13/2024, has just been added to the opportunity. This Addendum extends the RFA application due date to 4/24/2024 at 4pm ET. Please click on View Grant Opportunity to view this material. The New York State Department of Health (NYSDOH) and the Dormitory Authority of the State of New York (DASNY) announce the availability of funds under the Statewide Health Care Facility Transformation Program IV (SHCFTP IV), as established pursuant to Section 2825-g (7) of the Public Health Law (PHL), accompanying capital appropriations, and Section 1680-r of the Public Authorities Law (PAL), to provide grants in support of capital projects directly related to residential and community-based alternatives to the traditional model of nursing home care. Subdivision 7 of Section 2825-g of the PHL and Chapter 54 of the Laws of 2022 authorized up to $50,000,000 for awards to residential and community- based alternatives to the traditional model of nursing home care. Projects shall not receive awards under both this RFA and the Kings County Health Care Transformation Program (PHL §2825-a) or the Oneida County Health Care Transformation Program (PHL §2825-b).PLEASE NOTE: Letter of Interest is not required. Questions are due February 14, 2024 and answers will be posted on or about March 6, 2024. Please see RFA for further info. To apply for this opportunity please go to the top of this page and login to the Grants Gateway. Search for “Available Opportunities” and look for the grant opportunity name listed above.

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to support early-career academic scientists interested in transitioning to entrepreneurship while also supporting the transfer of technology from academic laboratories into small businesses. Both small businesses and universities are drivers of technological innovation in the United States (U.S.), often working together to advance innovative ideas into products that can benefit the U.S. population. While most NIH funding supports basic research in university laboratories, the NIH also supports innovative technology development in U.S. small businesses through its SBIR and STTR programs. As technologies transition from academic discovery to small businesses, two common challenges arise, identifying the right team with the right expertise to take the product into a small business, and funding for early-stage technology development. This NOFO seeks to address both challenges simultaneously by having two equally important goals: entrepreneurial mentoring support, and product development support.

The "DoD Tick-Borne Disease, Therapeutic/Diagnostic Research Award" is a grant aimed at supporting the development of new treatments and diagnostic methods for tick-borne diseases, with a focus on improving patient care and quality of life for military service members, veterans, their families, and the general public.

This grant provides funding for organizations experienced in wetland management to acquire, restore, and create wetlands in the Lake Erie and Saginaw Bay watersheds, promoting ecological health and community engagement.

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support the next stage of development for cancer-relevant projects that were previously funded under SBIR or STTR Phase II awards from any Federal agency. The purpose of this NOFO is to facilitate the transition of SBIR or STTR Phase II projects to the commercialization stage. This NOFO is expected to promote partnerships between Federally-funded SBIR or STTR Phase II awardees and third-party investors and/or strategic partners to facilitate and accelerate the capital-intensive steps that are required to commercialize new products and services. Applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the Phase IIB Bridge Award project period. It is expected that the level of this independent third-party funding will be equal to or greater than the NCI funds being requested throughout the Phase IIB Bridge Award project period. Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate but are not required.

The DoD Tick-Borne Disease, Idea Development Award is a grant aimed at funding innovative research that could significantly advance the understanding and treatment of Lyme disease and other tick-borne diseases, ultimately improving the lives of military personnel, veterans, their families, and the general public.

This Notice informs that NIA intends to publish a Notice of Funding Opportunity (NOFO) inviting applications from mid-career investigators for mentored career enhancement awards focused on cross-disciplinary training to broaden and strengthen the investigator's capability to lead future comparative studies of the factors contributing to differences in life spans between human and nonhuman primate species. The NOFO is intended to provide support for experienced investigators with expertise in human and/or nonhuman primate (NHP) studies to do the following: 1) Augment or redirect their research program by acquiring expertise in other fields related to comparative primate research and aging 2) Develop collaborations with research fields with which they do not commonly interact This Notice is being provided to allow potential applicants sufficient time to identify potential mentors and prepare well-developed career enhancement plans. The NOFO is expected to be published in June 2024 with an anticipated application due date in November 2024. These are estimated time frames, and they may change. The NOFO is expected to utilize the K18 Career Enhancement Award activity code. It is expected that the NOFO will not allow clinical trials. Additional details of the planned NOFO are provided below.

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications to support the archiving and documentation of existing data sets within the scientific mission of the NICHD in order to enable secondary analysis of these data by the scientific community. The highest priority is to archive original data collected with NICHD funding. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The NOFO is expected to be published in July 2024 with an expected application due date in October 2024. This NOFO will utilize the R03 activity code. Details of the planned NOFO are provided below.

The National Institute on Alcohol Abuse and Alcoholism ( NIAAA) intends to reissue RFA-AA-23-001, Specialized Alcohol Research Centers (P50, Clinical Trial Optional), by publishing a NOFO to solicit applications for a broad-based Alcohol Research Centers program to foster and conduct interdisciplinary, collaborative research on Alcohol Use Disorder (AUD), alcohol misuse and alcohol-related problems, and other health-related consequences across the lifespan. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The NOFO is expected to be published in Spring 2024 with an expected application due date in Fall 2024. This NOFO will utilize the P50 activity code. Details of the planned NOFO are provided below.

trainer program to educate, train, and prepare jail and prison staff so they are equipped to appropriately interact with people in a carceral setting who have mental illness (MI) and intellectual and developmental disabilities (IDD). This training should be developed by an institution of higher education or non-profit, for profit or tribal in conjunction with health care and corrections professionals to ensure a multidisciplinary approach. The training must focus on understanding behavioral health, including MI and substance use disorders, IDD, developing empathy, navigating community resources, and de-escalation skills and practical application training of those skills in a trauma-informed manner for all staff working in prisons and jails. The centerpiece of this training must be a 40-hour CIT train-the-trainer program.

Proposers must retrieve the instructions document (zip file) associated with the application package for this opportunity as there is at least one required form that must be attached to the submitted proposal package. The National Aeronautics and Space Administration (NASA) Science Mission Directorate (SMD) released its annual omnibus Research Announcement (NRA), Research Opportunities in Space and Earth Sciences (ROSES) 2024 (OMB Approval Number 2700-0092, CFDA Number 43.001) on February 14, 2024. In this case "omnibus" means that this NRA has many individual program elements, each with its own due dates and topics. All together these cover the wide range of basic and applied supporting research and technology in space and Earth sciences supported by SMD. Awards will be made as grants, cooperative agreements, contracts, and inter- or intra-agency transfers, depending on the nature of the work proposed, the proposing organization, and/or program requirements. However, most extramural research awards deriving from ROSES will be grants, and many program elements of ROSES specifically exclude contracts, because contracts would not be appropriate for the nature of the work solicited. The typical period of performance for an award is three years, but some programs may allow up to five years and others specify shorter periods. In most cases, organizations of every type, Government and private, for profit and not-for-profit, domestic and foreign (with some caveats), may submit proposals without restriction on teaming arrangements. Tables listing the program elements and due dates (Tables 2 and 3), a table that provides a very top level summary of proposal contents (Table 1), and the full text of the ROSES-2024 "Summary of Solicitation", may all be found NSPIRES at http://solicitation.nasaprs.com/ROSES2024. This synopsis is associated with one of the individual program elements within ROSES, but this is a generic summary that is posted for all ROSES elements. For specific information on this particular program element download and read the PDF of the text of this program element by going to Tables 2 or 3 of this NRA at http://solicitation.nasaprs.com/ROSES2024table2 and http://solicitation.nasaprs.com/ROSES2024table3, respectively, click the title of the program element of interest, a hypertext link will take you to a page for that particular program element. On that page, on the right side under "Announcement Documents" the link on the bottom will be to the PDF of the text of the call for proposals. For example, if one were interested in The Lunar Data Analysis Program (NNH24ZDA001N-LDAP) one would follow the link to the NSPIRES page for that program element and then to read the text of the call one would click on C.8 Lunar Data Analysis Program (.pdf) to download the text of the call. If one wanted to set it into the context of the goals, objectives and know the default rules for all elements within Appendix C, the planetary science division, one might download and read C.1 Planetary Science Research Program Overview (.pdf) from that same page. While the letters and numbers are different for each element within ROSES (A.12, B.7, etc.) the basic configuration is always the same, e.g., the letter indicates the Science Division (A is Earth Science, B is Heliophysics etc.) and whatever the letter, #1 is always the division overview. Frequently asked questions for ROSES are posted at http://science.nasa.gov/researchers/sara/faqs. Questions concerning general ROSES-2024 policies and procedures may be directed to Max Bernstein, Lead for Research, Science Mission Directorate, at sara@nasa.gov, but technical questions concerning specific program elements should be directed to the point(s) of contact for that particular element, who may be found either at the end of the individual program element in the summary table of key information or on the web list of topics and points of contact at: http://science.nasa.gov/researchers/sara/program-officers-list. Not all program elements are known at the time of the release of ROSES. To be informed of new program elements or amendments to this NRA, proposers may subscribe to: (1) The SMD mailing lists (by logging in at http://nspires.nasaprs.com and checking the appropriate boxes under "Account Management" and "Email Subscriptions"), (2) The ROSES-2024 blog feed for amendments, clarifications, and corrections to at https://science.nasa.gov/researchers/solicitations/roses-2024/, and (3) The ROSES-2024 due date Google calendars (one for each science division). Instructions are at https://science.nasa.gov/researchers/sara/library-and-useful-links (link from the words due date calendar).

The Nebraska SBIR/STTR Initiative provides financial assistance to small businesses in Nebraska participating in the federal SBIR/STTR programs. This state initiative offers Phase 0 assistance to help businesses apply for federal Phase 1 funding and matching funds for successful Phase 1 and Phase 2 federal awards. The initiative aims to promote innovation and technology transfer among small businesses in Nebraska, with a total fund availability of up to $6 million per year. Grant renewed every year. Grant Annual opening/closing deadline: July 1st to June 30th

The FY24 RCRP Concept Award supports highly innovative, untested, potentially groundbreaking novel concepts in rare cancers. The Concept Award is not intended to support an incremental progression of an already established research project; instead, it allows Principal Investigators (PIs) the opportunity to pursue serendipitous observations. Preliminary data are not required. This award mechanism supports high-risk studies that have the potential to reveal entirely new avenues for investigation. Applications must describe how the new idea will enhance the existing knowledge of rare cancers or develop an innovative and novel course of investigation. Research completed through a Concept Award may generate sufficient preliminary data to enable the PI to prepare an application for future research.Reviewers will be blinded to the identity of the Principal Investigator (PI), collaborator(s), and their organization(s). Refer to Section II.D.2.b.i., Full Application Submission Type, for more information.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 RCRP prioritiesInnovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in women's health outcomes and/or advancing knowledge for women's health.All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (https://www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs, and other federal government agencies are highly encouraged.DOD FY24 Rare Cancers Concept Award 5These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.Clinical trials are not allowed. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.

The EHDA supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the TSC research field. The studies supported by this award mechanism are expected to generate preliminary data for future avenues of scientific investigation. The proposed research project should include a well-formulated, testable hypothesis based on a strong scientific rationale and study design. Applications should demonstrate the ability to achieve interpretable results in the absence of preliminary data supporting the hypothesis.The following are important aspects of the EHDA: Innovation: Innovative research may introduce a new paradigm, challenge existing paradigms, examine existing problems from new perspectives, or exhibit other highly creative qualities. Research that is an incremental advance upon published data is not considered innovative and is not consistent with the intent of the award mechanism. Although not all-inclusive, the following examples are ways in which the proposed research project may be innovative: Explores a novel idea and/or research question in TSC research and/or patient care. Uses or develops novel methods or technologies to address a question in TSC research and/or patient care. Applies or adapts existing methods or technologies for novel TSC research or clinical purposes that differ fundamentally from those originally intended.

The CTRA supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including diagnosis, prognosis, or treatment of TSC. Projects supported by this award mechanism may include, but are not limited to: Studies moving from preclinical to clinical research and/or the reverse; or analyzing human anatomical substances and/or data associated with completed clinical trials to understand the mechanism of action, or to improve diagnosis, prognosis, or treatment. Studies advancing clinical trial readiness through development of biomarkers, clinical endpoints, and validation of pharmacokinetics/pharmacodynamics. Pilot clinical trials, where limited clinical testing (e.g., small sample size) of a novel intervention to produce information on diagnostic or therapeutic effectiveness, safety, tolerability, or mechanisms of action. These studies should be aimed at obtaining preliminary data leading to the development of interventions with the potential to improve TSC outcomes. New Studies improving clinical care of TSC encompassing the analysis of existing real-world clinical practice data to develop/improve guidelines for better outcomes in defined areas relevant to the FY24 TSCRP focus areas, include but are not limited to epilepsy surgery, tumor resection, reproductive health, perinatal surveillance and care, etc.Preclinical studies may be appropriate but must include a clinical component. Projects that are strictly animal research will not be considered for CTRA funding and should consider other FY24 TSCRP funding opportunities.

The IDA promotes ideas that have the potential to yield high-impact findings and new avenues of investigation. This award mechanism supports conceptually innovative research that could ultimately lead to critical discoveries in TSC research and/or improvements in patient care. Research projects should include a well-formulated, testable hypothesis based on strong preliminary data and scientific rationale. The following are important aspects of the IDA: Impact: Applications should articulate both the short- and long-term impact of the proposed research. High-impact research will, if successful, significantly advance TSC research and/or patient care. Innovation: Innovative research may introduce a new paradigm, challenge existing paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities that may include high-risk/potentially high-gain approaches to TSC research. Research that is merely an incremental advance (to the next logical step) is not considered innovative. Preliminary Data: Unpublished results from the laboratory of the Principal Investigator (PI) or collaborators named on this application, and/or data from the published literature that are relevant to TSC and the proposed research project, are required. New-to-the-Field Investigator (NFI): The FY24 TSCRP IDA mechanism encourages applications from investigators in the early stages of their TSC research career. The NFI Option is designed to support the continued development of promising independent investigators that are early in their faculty appointments and/or the transition of established investigators from other research fields into TSC research. Applications to the NFI Option will compete separately from Established Investigators submitting to the regular IDA. PIs applying under the NFI category are strongly encouraged to strengthen their applications through collaboration with investigators experienced in TSC research and/or possessing other relevant expertise as demonstrated by a record of funding and publications. See Attachment 8: Eligibility Statement.

This funding opportunity supports landowners, watershed groups, and nonprofits in Montana to improve fish habitats and populations by restoring natural stream channels, enhancing fish passage, and protecting essential spawning areas.

This grant provides funding for individuals conducting original research on Wyoming's history, with a preference for proposals from Wyoming residents that demonstrate public benefit.

The FY24 RCRP RCDA supports the development of clinical or preclinical data sets and research resources that advance the field of rare cancers research and ultimately improve outcomes for individuals with rare cancers. Major gaps in patient care of rare cancers include lack of communication and dissemination strategies for rare cancers research and clinical findings within communities; lack of therapeutics and mechanistic studies to inform treatment development; lack of research and clinical resources, including patient tissues, cell, and tumor models; and lack of infrastructure for sharing data and other resources.The intent of this funding opportunity is to develop research platforms that can share resources and knowledge pertaining to available preclinical or clinical research models, molecular pathways, and therapeutic approaches to facilitate collaboration and information sharing among stakeholders such as researchers, patients, caregivers, clinicians, and other members of the rare cancers community.Clinical or preclinical datasets should strive to integrate or develop the following research resources. This list is not all-inclusive: Building and sharing rare tumor biospecimen repository with clinical annotation Databases/banks for centralizing and sharing data for patient registries that can be accessed globally Centralizing and sharing research models and molecular data related to genomics/ transcriptomics/immune profiling/proteomics/metabolomics/methylomics/bioinformatics Generating a data/reagent/model exchange program where researchers can list resources that they are willing to share and are tagged with indications that may be relevant Platform to enable or leverage longitudinal studies of disease natural history and treatment response Development of novel methods and systems for collection, sharing, and analysis of data or biospecimensApplicants should include a well-formulated project design based on a strong scientific rationale and clearly articulate how the proposed resource platform or community development addresses an unmet need in rare cancers research. Applicants should explain the advantage of their approach to developing resources or community versus standard methodologies, techniques, or scopes. A clear plan for collaboration and data sharing needs to be demonstrated. It is critical to demonstrate how the outcome of the proposed project can benefit type(s) or sub-type(s) of rare cancers. It is encouraged for the research platform/resource to have an effect on multiple types or sub-types of rare cancers.Key Elements of the Resource and Community Development Award are as follows: Impact: Outcomes of the RCDA must have potential for major impact on an unmet need in rare cancers research. A resource, as developed in the proposed research, should aim forDOD FY24 Rare Cancers Resource and Community Development Award 5long-term anticipated advantages toward greatly improving outcomes for people with rare cancers. Patient Advocate Partnership: Applications to the RCDA funding opportunity are required to include patient advocates who are involved with patient advocacy organization(s). The research team must include at least two rare cancers patient advocates who will be early and integral partners throughout the planning and implementation of the research project. Patient advocates should be involved in the development of the research question, project design, oversight, and evaluation, as well as other significant aspects of the proposed project. Interactions with other team members should be well integrated and ongoing, and not limited to attending seminars and semi-annual meetings. The patient advocates must be individuals who have been directly impacted by a rare cancer either by being diagnosed themselves or as a caretaker/family member of a patient, and they should be active in a cancer advocacy organization or within a support group focused on their rare cancer. Their role should be focused on providing objective input on the research and its potential impact for individuals with or at risk for a rare cancer. The patient advocates should have a high level of understanding of current rare cancers research. Preliminary Data: Due to the developmental nature of this award, preliminary data are not required but may be included, if available, to address the feasibility of the resource to be developed. Whether or not preliminary data are included, applications must apply solid scientific rationale and logical reasoning based on existing knowledge to the development of the proposed product. Clinical Research: Research involving human subject use is permitted under this mechanism but is restricted to studies without clinical trials. Clinical trials will not be supported. Applications focused on clinical research should demonstrate how the study will leverage clinical information to address knowledge gaps in the development of platforms that can be utilized for sharing data and tissue, the development of clinical annotation datasets, process development, and/or infrastructure development. Applied Research: Preclinical studies utilizing or creating animal models to further research into rare cancers may be supported by this funding opportunity. The RCDA is intended to support projects that will have the potential to move beyond the realm of basic research, with results that may impact clinical research or patient outcomes. Community Building: A plan describing how the rare cancers stakeholder community will be built/enhanced and the communitys involvement with developing the resource platform is required. It is also important to justify how the community is essential for the development and sustainment of the resource platform. Dissemination: A Dissemination Plan is required. The plan should describe the means by which the fully developed resource platform will be made easily available to the scientific and/or clinical community. Dissemination of resource platform will play a major role by not only educating the rare cancer community about the recent progress, but also help to develop an informational network.DOD FY24 Rare Cancers Resource and Community Development Award 6 Sustainment: A plan that outlines the sustainability of the resource in the future is required. The plan should detail the types of rare cancers that are less studied in the collaborations and the resources to be gathered, annotated, and sustained. Additional expansion and feasibility plans should be included. It is important to demonstrate how the outcomes of the current award will be continued and eventually will help the rare care cancer community, beyond the award period.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 RCRP priorities.Collaborations between researchers at military or Veteran institutions and non-military institutions are strongly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the partners bring to the research effort, ultimately advancing cancer research that is of significance to the Warfighter, military Families, and the American public.Innovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in womens health outcomes and/or advancing knowledge for women's health.All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (https://www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.